In vitro activity of tigecycline in bacterial strains isolated in clinical specimens from patients seen at a university hospital
Article Sidebar
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloads
Societal impact
Main Article Content
Abstract
Introduction: The steady increase in bacterial resistance to antibiotics, will require new therapeutic strategies. Tigecycline is a new antibiotic derived from minocycline, which has demonstrated excellent in vitro activity against a broad spectrum of microorganisms. Objective: To describe the sensitivity of Gram-positive and Gram-negative aerobic bacteria to tigecycline, isolated from clinical samples, in a fourth-level hospital.
Methods: The identification was carried out by conventional methods of identification and the susceptibility study to tigecycline by the disk diffusion method, to isolated bacteria specimens (except urine) from patients treated in the emergency and outpatient department.
Results: A total of 2515 bacteria strains were included. 100% of strains of Staphylococcus aureus (651), Staphylococcus coagulase negative (382) and Enterococcus spp. (276), were susceptible to tigecycline. The largest number of Enterobacteriaceae tested, Escherichia coli (511) had a sensitivity of 99.8%, Klebsiella pneumoniae (332) a 93.1% and Enterobacter cloacae (129) of 96.9%. The strains that showed resistance mechanisms such as Staphylococcus spp. oxacillin-resistant or Enterobacteriaceae producing extended spectrum beta lactamases showed high rates of susceptibility to tigecycline.
Conclusions: Tigecycline, as with most studies conducted in other regions of the world, presented an excellent in vitro activity in bacteria isolated in the clinical samples from this hospital and therefore could be an option in treating both as empirical therapy of infections in which its use is indicated.
Article Details
References
Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, et al. The epidemic of antibioticresistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008; 46(2):155-64.
Pankey GA. Tigecycline. J Antimicrob Chemother. 2005; 56(3):470-80.
Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis. 2001; 40(4):173-7.
Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2000; 38(3):177-9.
Fritsche TR, Kirby JT, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections. Diagn Microbiol Infect Dis. 2004; 49(3):201-9.
Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect. Dis 2000; 36(1):19-36.
Betriu C, Rodríguez-Avial I, Gómez M, Culebras E, López F, Alvarez J, et al.; Spanish Tigecycline Group. Timicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study. Diagn Microbiol Infect Dis. 2006; 56(4):437-44.
Milatovic D, Schmitz FJ, Verhoef J, Fluit AC. Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates. Antimicrob Agents Chemother. 2003; 47(1):400-4.
Zhang YY, Zhou L, Zhu DM, Wu PC, Hu FP, Wu WH, et al. In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn Microbiol Infect Dis. 2004; 50(4):267-81.
Waites KB, Duffy LB, Dowzicky MJ. Antimicrobial susceptibility among pathogens collected from hospitalized patients in the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial. Antimicrob Agents Chemother. 2006; 50(10):3479- 84.
Isenberg HD, Washington JA, Ballows A, Sonnenwirth AC. Collection, handling, and processing of specimens. In: Lennette EH, Ballows A, Hausler WJ Jr, Shadomy HJ, editors. Manual of clinical microbiology. Washington, DC: American Society for Microbiology; 1985. p. 73- 98.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Disk Susceptibility Tests: approved Standard. 9. ed. Wayne: CLSI; 2006. M2- A9.
Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: informational Supplement. 16. ed. Wayne: CLSI; 2006. M100-S16.
Hope R, Warner M, Potz NA, Fagan EJ, James D, Livermore DM. Activity of tigecycline against ESBL-producing and AmpC-hyperproducing Enterobacteriaceae from south-east England. J Antimicrob Chemother. 2006; 58(6):1312-4.
Samra Z, Ofir O, Lishtzinsky Y, Madar-Shapiro L, Bishara J. Outbreak of carbapenem-resistant Klebsiella pneumoniae producing KPC-3 in a tertiary medical centre in Israel. Int J Antimicrob Agents. 2007; 30(6):525-9.
Naesens R, Ursi JP, Van Schaeren J, Jeurissen A. In vitro activity of tigecycline against multidrug-resistant Enterobacteriaceae isolates from a Belgian hospital. Eur J Clin Microbiol Infect Dis. 2009; 28(4):381-4.
Halstead DC, Abid J, Dowzicky MJ. Antimicrobial susceptibility among Acinetobacter calcoaceticusbaumannii complex and Enterobacteriaceae collected as part of the Tigecycline Evaluation and Surveillance Trial. J Infect. 2007; 55(1):49-57.
Reinert RR, Low DE, Rossi F, Zhang X, Wattal C, Dowzicky MJ. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother. 2007; 60(5):1018-29.
Kresken M, Leitner E, Brauers J, Geiss HK, Halle E, von Eiff C, et al.; German Tigecycline Evaluation Surveillance Trial Study Group. Susceptibility of common aerobic pathogens to tigecycline: results of a surveillance study in Germany. Eur J Clin Microbiol Infect Dis. 2009; 28(1):83-90.
Bouchillon SK, Iredell JR, Barkham T, Lee K, Dowzicky MJ. Comparative in vitro activity of tigecycline and other antimicrobials against Gram-negative and Gram-positive organisms collected from the AsiaPacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST). Int J Antimicrob Agents. 2009; 33(2):130-6.
Rossi F, García P, Ronzon B, Curcio D, Dowzicky MJ. Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics. Braz J Infect Dis. 2008; 12(5):405-15.
Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents. 2009 Mar 31 [Epub ahead of print].
Martínez E, Alquichire C, Pérez C, Prada G, Rozo V, Larotta J. Comparación de la actividad in vitro de la tigeciclina contra microorganismos causantes de infección en pacientes hospitalizados en Colombia: estudio de evaluación y vigilancia de tigeciclina,TEST. Infectio. 2007; 11(4):159-70.
Fernández Canigia L, Kaufman S, Lanata L, Vay C, Giovanakis M, Bantar C; Argentinean Tigecycline Surveillance Group. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina. Chemotherapy. 2009; 55(1):20-7.
Henwood CJ, Gatward T, Warner M, James D, Stockdale MW, Spence RP, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother. 2002; 49(3):479-87.
Jones RN, Ferraro MJ, Reller LB, Schreckenberger PC, Swenson JM, Sander HS. Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol. 2007; 45(1):227– 30.
Thamlikitkul V, Tiengrim S. Effect of different MuellerHinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp. J Antimicrob Chemother. 2008; 62(4):847-8.